Literature DB >> 20085797

AKT regulates BRCA1 stability in response to hormone signaling.

Andrew C Nelson1, Traci R Lyons, Christian D Young, Kirk C Hansen, Steven M Anderson, Jeffrey T Holt.   

Abstract

The observation that inherited mutations within BRCA1 result in breast and ovarian cancers suggests a functional relationship may exist between hormone signaling and BRCA1 function. We demonstrate that AKT activation promotes the expression of BRCA1 in response to estrogen and IGF-1 receptor signaling, and the rapid increase in BRCA1 protein levels appears to occur independently of new protein synthesis. Further, we identify a novel AKT phosphorylation site in BRCA1 at S694 which is responsive to activation of these signaling pathways. These data suggest AKT phosphorylation of BRCA1 increases total protein expression by preventing proteasomal degradation. AKT activation also appears to support nuclear localization of BRCA1, and co-expression of activated AKT with BRCA1 decreases radiation sensitivity, suggesting this interaction has functional consequences for BRCA1's role in DNA repair. Targets within this pathway could provide strategies for modulation of BRCA1 protein, which may prove therapeutically beneficial for breast and ovarian cancer treatment. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20085797      PMCID: PMC4548798          DOI: 10.1016/j.mce.2010.01.019

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  69 in total

1.  Adenovirus transduction of 3T3-L1 cells.

Authors:  D J Orlicky; J Schaack
Journal:  J Lipid Res       Date:  2001-03       Impact factor: 5.922

Review 2.  The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity.

Authors:  Richard Baer; Thomas Ludwig
Journal:  Curr Opin Genet Dev       Date:  2002-02       Impact factor: 5.578

3.  BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage.

Authors:  Ronit I Yarden; Sherly Pardo-Reoyo; Magda Sgagias; Kenneth H Cowan; Lawrence C Brody
Journal:  Nat Genet       Date:  2002-02-11       Impact factor: 38.330

4.  Genetic analysis of BRCA1 function in a defined tumor cell line.

Authors:  R Scully; S Ganesan; K Vlasakova; J Chen; M Socolovsky; D M Livingston
Journal:  Mol Cell       Date:  1999-12       Impact factor: 17.970

5.  Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity.

Authors:  H Ruffner; C A Joazeiro; D Hemmati; T Hunter; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

6.  Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains.

Authors:  Y Jin; X L Xu; M C Yang; F Wei; T C Ayi; A M Bowcock; R Baer
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

7.  BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to estrogen.

Authors:  M A Spillman; A M Bowcock
Journal:  Oncogene       Date:  1996-10-17       Impact factor: 9.867

Review 8.  Hormonal prevention of hereditary breast cancer.

Authors:  S A Narod
Journal:  Ann N Y Acad Sci       Date:  2001-12       Impact factor: 5.691

9.  Estrogen upregulation of BRCA1 expression with no effect on localization.

Authors:  D Romagnolo; L A Annab; T E Thompson; J I Risinger; L A Terry; J C Barrett; C A Afshari
Journal:  Mol Carcinog       Date:  1998-06       Impact factor: 4.784

10.  Regulation of progesterone receptor signaling by BRCA1 in mammary cancer.

Authors:  Pragati Katiyar; Yongxian Ma; Saijun Fan; Richard G Pestell; Priscilla A Furth; Eliot M Rosen
Journal:  Nucl Recept Signal       Date:  2006-04-28
View more
  21 in total

1.  Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers.

Authors:  Susan L Neuhausen; Sean Brummel; Yuan Chun Ding; Linda Steele; Katherine L Nathanson; Susan Domchek; Timothy R Rebbeck; Christian F Singer; Georg Pfeiler; Henry T Lynch; Judy E Garber; Fergus Couch; Jeffrey N Weitzel; Andrew Godwin; Steven A Narod; Patricia A Ganz; Mary B Daly; Claudine Isaacs; Olufunmilayo I Olopade; Gail E Tomlinson; Wendy S Rubinstein; Nadine Tung; Joanne L Blum; Daniel L Gillen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-06-27       Impact factor: 4.254

Review 2.  Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer.

Authors:  Tzu-Ting Huang; Erika J Lampert; Cynthia Coots; Jung-Min Lee
Journal:  Cancer Treat Rev       Date:  2020-04-10       Impact factor: 12.111

3.  Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer.

Authors:  Maria E Gonzalez; Matthew L DuPrie; Heather Krueger; Sofia D Merajver; Alejandra C Ventura; Kathy A Toy; Celina G Kleer
Journal:  Cancer Res       Date:  2011-03-15       Impact factor: 12.701

4.  Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.

Authors:  Yong Weon Yi; Hyo Jin Kang; Hee Jeong Kim; Jae Seok Hwang; Antai Wang; Insoo Bae
Journal:  Mol Carcinog       Date:  2012-04-04       Impact factor: 4.784

Review 5.  At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy.

Authors:  Neil Vasan; Lewis C Cantley
Journal:  Nat Rev Clin Oncol       Date:  2022-04-28       Impact factor: 65.011

6.  Power of PTEN/AKT: Molecular switch between tumor suppressors and oncogenes.

Authors:  Yingqiu Xie; Sanzhar Naizabekov; Zhanlin Chen; Tursonjan Tokay
Journal:  Oncol Lett       Date:  2016-05-26       Impact factor: 2.967

7.  Transcriptional and posttranslational regulation of insulin-like growth factor binding protein-3 by Akt3.

Authors:  Quanri Jin; Hyo-Jong Lee; Hye-Young Min; John Kendal Smith; Su Jung Hwang; Young Mi Whang; Woo-Young Kim; Yeul Hong Kim; Ho-Young Lee
Journal:  Carcinogenesis       Date:  2014-06-18       Impact factor: 4.944

Review 8.  AKT1/BRCA1 in the control of homologous recombination and genetic stability: the missing link between hereditary and sporadic breast cancers.

Authors:  Josée K Guirouilh-Barbat; Therese Wilhelm; Bernard S Lopez
Journal:  Oncotarget       Date:  2010-12

Review 9.  Therapeutic targeting of replicative immortality.

Authors:  Paul Yaswen; Karen L MacKenzie; W Nicol Keith; Patricia Hentosh; Francis Rodier; Jiyue Zhu; Gary L Firestone; Ander Matheu; Amancio Carnero; Alan Bilsland; Tabetha Sundin; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Bill Helferich; Chandra S Boosani; Gunjan Guha; Maria Rosa Ciriolo; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; Dipita Bhakta; Dorota Halicka; Elena Niccolai; Katia Aquilano; S Salman Ashraf; Somaira Nowsheen; Xujuan Yang
Journal:  Semin Cancer Biol       Date:  2015-04-11       Impact factor: 15.707

Review 10.  Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System.

Authors:  W Ruprecht Wiedemeyer; Jessica A Beach; Beth Y Karlan
Journal:  Front Oncol       Date:  2014-03-03       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.